AC
CLSD

Armistice Capital’s Clearside Biomedical CLSD Stock Holding History

Armistice Capital’s Portfolio CLSD Stock Details CLSD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-142,400
Closed -$2.78M – 273
2024
Q2 		$2.78M Sell
142,400
-121,333
-46% -$2.34M 0.03% 138
2024
Q1 		$6.05M Buy
+263,733
New +$5.68M 0.08% 117

Other funds holding CLSD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GGH
GCM Grosvenor Holdings Chicago, Illinois $901M AUM 28.6% 1-Year Est. Return

Armistice Capital's CLSD Position: Q3 2024 in Review

Armistice Capital sold out of Clearside Biomedical (CLSD) in Q3 2024, closing a stake of 142,400 shares — an estimated $2.78M sold.

Armistice Capital first reported a position in CLSD in Q1 2024 and held it in 2 quarters. The position peaked at $6.05M in Q1 2024. 48 funds tracked by Wall St. Rank hold CLSD as of Q3 2024.

  • Armistice Capital reported no remaining Clearside Biomedical position as of Q3 2024 after selling out during the quarter.
  • Armistice Capital sold 142,400 Clearside Biomedical shares in Q3 2024, an estimated $2.78M.
  • Armistice Capital first reported a position in Clearside Biomedical in Q1 2024 and held it in 2 quarters.
  • Armistice Capital's Clearside Biomedical position peaked at $6.05M in Q1 2024.
  • 48 funds tracked by Wall St. Rank held Clearside Biomedical as of Q3 2024.

Based on Armistice Capital's 13F filing for Q3 2024, filed 14 Nov 2024.